Drug Information

Drug General Information
Drug ID
D0M3GQ
Former ID
DIB013947
Drug Name
BL-22
Synonyms
CAT-3888; GCR-3888; RFB4(dsFv)-PE38; PE38-conjugated anti-CD22 immunotoxin, NCI/Cambridge Antibody Technology/AstraZeneca
Drug Type
Antibody
Indication Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10:C91.0] Phase 2 [522698]
Company
National Cancer Institute
Target and Pathway
Target(s) B-cell receptor CD22 Target Info [530776]
KEGG Pathway Cell adhesion molecules (CAMs)
Hematopoietic cell lineage
B cell receptor signaling pathway
PANTHER Pathway B cell activation
Pathway Interaction Database BCR signaling pathway
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways B Cell Receptor Signaling Pathway
References
Ref 522698ClinicalTrials.gov (NCT00924040) Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia. U.S. National Institutes of Health.
Ref 530776Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.